You can search in free text – simply type the disease, drug, company name, or other detail into the Search bar below and click Apply
Displaying 13 of 13
HiberCell, Inc.
EA Page: https://www.hibercell.com
Kite, A Gilead Company
Axicabtagene Ciloleucel Expanded Access Study
Conditions: Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma, Relapsed/Refractory Transformed Follicular Lymphoma, Relapsed/Refractory High-Grade B-Cell Lymphoma
A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968